Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men.

McEneny J, McPherson PA, McGinty A, Hull SS, McCance DR, Young IS.

Ann Clin Biochem. 2013 Jan;50(Pt 1):20-4. doi: 10.1258/acb.2012.012019. Epub 2012 Nov 12.

PMID:
23148280
2.

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W.

Diabetes Care. 2003 Sep;26(9):2588-94.

PMID:
12941723
3.
4.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
5.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010.

PMID:
18940393
6.

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T.

Circulation. 2008 Apr 22;117(16):2123-30. doi: 10.1161/CIRCULATIONAHA.107.746610. Epub 2008 Apr 14.

7.
8.

Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.

Carreón-Torres E, Rendón-Sauer K, Monter-Garrido M, Toledo-Ibelles P, Gamboa R, Menjivar M, López-Marure R, Luc G, Fievet C, Cruz D, Vargas-Alarcón G, Pérez-Méndez O.

Clin Chim Acta. 2009 Mar;401(1-2):37-41. doi: 10.1016/j.cca.2008.11.003. Epub 2008 Nov 12.

PMID:
19036342
9.
10.
11.

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

Coron Artery Dis. 2001 Aug;12(5):413-23.

PMID:
11491207
12.

Orlistat increases serum paraoxonase activity in obese patients.

Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, Illyés L, Winkler G, Katona EM, Paragh G.

Nutr Metab Cardiovasc Dis. 2007 May;17(4):268-73. Epub 2006 Jul 10.

PMID:
17134960
13.

Effects of pioglitazone on lipid and lipoprotein metabolism.

Betteridge DJ.

Diabetes Obes Metab. 2007 Sep;9(5):640-7. Review.

PMID:
17697057
14.

Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.

Circ Res. 2004 Oct 15;95(8):789-97. Epub 2004 Sep 23.

15.

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.

Paragh G, Seres I, Harangi M, Balogh Z, Illyés L, Boda J, Szilvássy Z, Kovács P.

Diabetes Metab. 2003 Dec;29(6):613-8.

PMID:
14707891
16.

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.

17.

Relationship between obesity and cardiovascular risk factors: findings from a multi-state screening project in the United States.

Joshi AV, Day D, Lubowski TJ, Ambegaonkar A.

Curr Med Res Opin. 2005 Nov;21(11):1755-61.

PMID:
16307695
18.

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

Chiquette E, Ramirez G, Defronzo R.

Arch Intern Med. 2004 Oct 25;164(19):2097-104.

PMID:
15505122
19.

Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial.

Juárez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, Caracas-Portilla NA, Posadas-Sánchez R, Cardoso-Saldaña GC, Goycochea-Robles MV, Silveira LH, Lino-Pérez L, Mas-Oliva J, Pérez-Méndez O, Posadas-Romero C.

Lupus. 2012 Jan;21(1):27-35. doi: 10.1177/0961203311422096. Epub 2011 Oct 12.

PMID:
21993383
20.

Supplemental Content

Support Center